1.13
-0.035(-3.00%)
Currency In USD
Address
37000 Grand River Avenue
Durham, MI 48335
United States of America
Phone
248 957 9024
Website
Sector
Healthcare
Industry
Biotechnology
Employees
18
First IPO Date
January 19, 2015
| Name | Title | Pay | Year Born |
| Mr. George Magrath M.B.A., M.D., M.S. | Chief Executive Officer & Director | 889,238 | 1984 |
| Mr. Bernhard Hoffmann M.B.A. | Senior Vice President of Corporate Development & Secretary | 434,100 | 1956 |
| Ms. Amy Zaremba Rabourn C.P.A., MAcc | Senior Vice President of Finance | 434,100 | 1981 |
| Dr. Ashwath Jayagopal Ph.D. | Chief Scientific & Development Officer | 565,368 | 1982 |
| Mr. Nirav Suresh Jhaveri C.F.A. | Chief Financial Officer | 575,916 | 1978 |
| Mr. Erik Sims | Director & Corporate Controller | 0 | N/A |
| Mr. Joseph K. Schachle MBA | Chief Operating Officer | 0 | 1965 |
| Ms. Bindu Manne | Head of Market Development & Commercialization | 0 | N/A |
| Dr. Benjamin R. Yerxa Ph.D. | President & Director | 0 | 1966 |
Opus Genetics, Inc., a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders. The company offers Phentolamine Ophthalmic Solution for reversal of mydriasis, as well as is in Phase III clinical trials for presbyopia and dim light or night vision disturbances. Its lead retinal product candidate is APX3330, a small-molecule inhibitor of reduction oxidation effector factor-1 protein that has completed Phase II clinical trial for the treatment of diabetic retinopathy. The company also develops APX2009 and APX2014 that are preclinical product candidates for retina indications. The company was formerly known as Ocuphire Pharma, Inc. Opus Genetics, Inc. was founded in 2018 and is headquartered in Farmington Hills, Michigan.